Signature Search Polestar: a comprehensive drug repurposing method evaluation assistant for customized oncogenic

Jinbo Zhang1,2, Shunling Yuan1, Wen Cao1

  • 1Department of Phytochemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.

PubMed
Abstract

Insights

Signature Search Polestar (SSP) optimizes anti-cancer drug repurposing by evaluating signature search methods (SSMs) and oncogenic signatures. This tool helps identify the best methods and gene signatures for improved drug discovery in oncology.

Area of Science:

  • Pharmacogenomics and Computational Biology
  • Oncology Drug Discovery
  • Bioinformatics Tools

Background:

  • High-throughput technologies generate large pharmacotranscriptomic datasets, particularly in oncology.
  • Signature search methods (SSMs) are crucial for anti-cancer drug screening and mechanism identification.
  • Performance of SSMs and oncogenic signature size vary, posing challenges for drug repurposing.

Purpose of the Study:

  • To develop an integrated webserver, Signature Search Polestar (SSP), for optimizing anti-cancer drug repurposing.
  • To evaluate and compare the performance of state-of-the-art SSMs using extensive pharmacotranscriptomic data.
  • To provide flexible strategies for utilizing optimal SSMs and customized oncogenic signatures.

Main Methods:

  • SSP integrates the LINCS L1000 pharmacotranscriptomic dataset with five SSMs (XSum, CMap, GSEA, ZhangScore, XCos).
  • The Benchmark module evaluates SSMs using Area Under the Curve and Enrichment Score based on drug annotations.
  • The Robustness module uses a drug self-retrieval performance score when annotations are limited.
  • The Application module offers single method, SS_all, and SS_cross screening strategies.

Main Results:

  • SSP facilitates the evaluation of various SSMs across different oncogenic signature sizes.
  • The tool enables robust performance assessment of SSMs even with limited drug annotations.
  • SSP provides adaptable screening strategies for personalized drug repurposing.

Conclusions:

  • SSP addresses the challenge of selecting optimal SSMs and oncogenic signatures for specific diseases.
  • The webserver enhances the efficiency and accuracy of anti-cancer drug repurposing.
  • SSP empowers researchers to leverage tailored approaches for novel therapeutic discoveries.